How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue

Drug Discovery Today

Volumn 15, Issue 11-12, 2010, Pages 411-415

  Giraldo, Jesús ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; G PROTEIN COUPLED RECEPTOR; RIMONABANT;

DRUG CLASSIFICATION; DRUG EFFICACY; DRUG SENSITIVITY; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 77954814265     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.04.004     Document Type: Short Survey

References (31)

1. Van Gaal L.F., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
2. Pi-Sunyer F.X., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J. Am. Med. Assoc. 2006, 295:761-775.
3. Despres J.P., et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 2005, 353:2121-2134.
4. Scheen A.J., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
5. Christensen R., et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007, 370:1706-1713.
6. Mitchell P.B., Morris M.J. Depression and anxiety with rimonabant. Lancet 2007, 370:1671-1672.
7. Bergman J., et al. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol. Behav. 2008, 93:666-670.
8. Jones D. End of the line for cannabinoid receptor 1 as an anti-obesity target?. Nat. Rev. Drug Discov. 2008, 7:961-962.
9. Giraldo J., et al. Assessing receptor affinity for inverse agonists: Schild and Cheng-Prusoff methods revisited. Curr. Drug Targets 2007, 8:197-202.
10. Costa T., Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:7321-7325.
11. Kenakin T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 2004, 65:2-11.
12. Salamone J.D., et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol. Behav. 2007, 91:383-388.
13. Di Marzo V. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Nat. Clin. Pract. Cardiovasc. Med. 2008, 5:610-612.
14. Di Marzo V., Despres J.P. CB1 antagonists for obesity-what lessons have we learned from rimonabant?. Nat. Rev. Endocrinol. 2009, 5:633-638.
15. Fong T.M., Heymsfield S.B. Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int. J. Obes. (Lond.) 2009, 33:947-955.
16. Kunos G., et al. Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?. Trends Pharmacol. Sci. 2009, 30:1-7.
17. Di Marzo V. The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008, 51:1356-1367.
18. Turu G., Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J. Mol. Endocrinol. 2010, 44:75-85.
19. Lee H.K., et al. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr. Top. Med. Chem. 2009, 9:482-503.
20. Price M.R., et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 2005, 68:1484-1495.
21. Franco R., et al. The two-state dimer receptor model: a general model for receptor dimers. Mol. Pharmacol. 2006, 69:1905-1912.
22. Rovira X., et al. The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol. Sci. 2010, 31:15-21.
23. Sun Y., et al. When a G protein-coupled receptor does not couple to a G protein. Mol. Biosyst. 2007, 3:849-854.
24. Brea J., et al. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol. Pharmacol. 2009, 75:1380-1391.
25. Kenakin T.P. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol. Sci. 2009, 30:460-469.
26. Kenakin T.P. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 2009, 8:617-626.
27. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 1995, 16:89-97.
28. Di Marzo V. CB(1) receptor antagonism: biological basis for metabolic effects. Drug Discov. Today 2008, 13:1026-1041.
29. Paul S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
30. Giraldo J. Agonist induction, conformational selection, and mutant receptors. FEBS Lett. 2004, 556:13-18.
31. Black J.W., Leff P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. Biol. Sci. 1983, 220:141-162.